Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th ...

Tumor Shrinkage of 50% and significant CA-125 biomarker reduction observed at 220 mg dose level Patient experienced only Grade 1 adverse events Represents second patient with PR to harbor PPP2R1A ...

Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging ...

SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced ...

FOG-001, the first and only direct β-catenin:TCF inhibitor, shows early clinical activity in a range of Wnt/β-catenin–driven tumors — reinforcing clinical development opportunities across both rare ...

Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease Clinical trials frequently include multiple ...

Werewolf Therapeutics updates on clinical trials, financial results, and plans for proprietary T cell engager development amidst strong cash position. Werewolf Therapeutics, Inc. announced significant ...

"We demonstrated a smartphone-based ML-assisted system for evaluating CAS and detecting active TAO using selfie images captured by a smartphone camera. The accuracy of this solution surpassed that of ...